US scientists have found.
Our results warrant additional investigation. Writing within an accompanying comment, Dr Steven Nissen from the Cleveland Clinic stated that the findings raise important questions about the safety of ARBs. He urged pharmaceutical businesses to supply regulators with complete trial data so that the possible hyperlink between ARBs and cancers can be investigated correctly. In the interim, we have to use ARBs, telmisartan particularly, with greater caution, Dr Nissen advised, adding that they must be reserved for individuals who are unable to take another class of blood pressure-lowering medication called angiotensin-transforming enzyme inhibitors. Martin Ledwick, head information nurse at Tumor Research UK, commented: It’s important that we try to understand all of the side-effects of medicines so that people can make the best choice about their treatment.However, our observed death rate at 28 days was lower than the rate in some other studies, although it was in line with the rate in more recent trials, in which death rates which range from 25 to 57 percent were reported.7,15 Nevertheless, the lower-than-expected rate of death led to an underpowered study. Consequently, we might not have detected distinctions in the incidence of some adverse events, rare events such as myocardial infarction especially. Septic shock is normally a significant risk factor for atrial fibrillation,17 and in our study, atrial fibrillation was significantly more common in the high-target group than in the low-target group.